Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.51 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference Transcript

May 27, 2020 / 02:00PM GMT
Release Date Price: $533.4 (-1.76%)
Aaron Gal
Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst

Hi, everybody, and thank you for joining us for this session of the SEC with Len Schleifer, CEO of Regeneron; and the IR team. I'm Ronny Gal, the -- I guess, biopharma analyst here at Bernstein. Len is with us fresh -- very fresh after, I guess, 2 days of talking to investors with the offering that rather came out in the last couple of days. I just learned it's the largest offering in the sector for a very, very long time. And that has gone through successfully. So congratulation, Len and the IR team. So a little bit of a post that set of issues, we have a nice time for us to discuss the business and how it looks forwards with potentially some new people who are now fresh investors in the company.

For those of you who have joined us, the investors, I want to mention to you that there's an interactive Q&A format that we're using here, called Pigeonhole. There's a link on the left side of your screen to access that application. When you click on the link, it will open up as a new window, and you can see

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot